Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001

Summary In the phase 3 QUAZAR AML‐001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral azacitidine (Oral‐AZA) maintenance significantly prolonged overall survival (OS) versus placebo. The impact of subsequent treatment following maintenance has not been evaluated. In this post hoc analysis, OS was estimated for patients who received subsequent AML therapy, and by regimen received (IC or lower‐intensity therapy). First subsequent therapy (FST) was administered after treatment discontinuation in 134/238 Oral‐AZA and 173/234 placebo patients. OS from randomization in patients who received FST after Oral‐AZA versus placebo was 17.8 versus 12.9 months (HR: 0.82 [95% CI: 0.64–1.04], median follow‐up: 56.7 months); OS from FST was similar between arms. Among patients who received injectable hypomethylating agents as FST, median OS was 8.2 versus 4.9 months in the Oral‐AZA versus placebo groups (HR: 0.66 [95% CI: 0.41–1.06]). Forty‐eight patients (16/238 Oral‐AZA, 32/234 placebo) received HSCT following treatment discontinuation, including six Oral‐AZA patients still in first remission; Oral‐AZA OS benefit persisted when censoring these patients. Oral‐AZA maintenance can prolong AML remission duration without negatively impacting survival outcomes after salvage therapies.